Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)
Phase 3
Completed
- Conditions
- Hypercholerolemia
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 136
- Registration Number
- NCT00157911
Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 187
- Registration Number
- NCT00156065
40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 218
- Registration Number
- NCT00159783
Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 260
- Registration Number
- NCT00156091
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 417
- Registration Number
- NCT00156117
Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
Phase 4
Completed
- Conditions
- Essential Hypertension
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 174
- Registration Number
- NCT00157963
A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)
Phase 4
Completed
- Conditions
- AsthmaAllergic Rhinitis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 31
- Registration Number
- NCT00157937
3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 488
- Registration Number
- NCT00159744
3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 489
- Registration Number
- NCT00159796
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 277
- Registration Number
- NCT00151424